Drug Profile
Research programme: cancer therapies - Cetek
Alternative Names: CTK 000147; CTK 100144; CTK 110Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cetek Corporation
- Class Small molecules
- Mechanism of Action Aurora kinase inhibitors; HSP90 heat-shock protein inhibitors; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 05 Dec 2007 Advanced Viral Research Corp. acquires certain assets originally owned by Cetek Corporation
- 20 Jul 2007 This programme is still in active development